medicines


The Comprehensive and Progressive Agreement for the Trans-Pacific Partnership: Data exclusivity and access to biologics
The agreement does not promise that the suspended provision on test data rule concerning biological medicines will remain suspended.
Intellectual property rights: Potential implications of the DCFTA for access to medicine
If the intellectual property provisions of the DCFTA are applied, this will have an impact on both the cost of patented medicines and undermine access to affordable medicines.
Can a US-India trade deal permanently alter the way Indians access medicines?
US-India IP engagements since 2006 have served the interests of the US through systematic undermining of the legislative safeguards in the Indian Patents Act.
Trump will insist NHS pays more for drugs in trade deal, says ambassador
Donald Trump will put the interests of corporate America first and demand that the NHS pays higher prices for US drugs in a free-trade deal with the UK, the outgoing British ambassador to Washington said.
Phase 1 US China trade deal: patent provisions
China agreed to extend patent terms for novel drugs "to compensate for unreasonable delays that occur in granting the patent or during pharmaceutical product marketing approvals."
India, Indonesia negotiating economic cooperation agreement
India and Indonesia are set to launch negotiations for a Comprehensive Economic Cooperation Agreement (CECA) to cover economic cooperation while trading in goods, services, and investments.
Blueprint for a human rights impact assessment of the planned comprehensive free trade agreement between EFTA and Mercosur
This study assesses the impact of the EFTA-Mercosur free trade agreement on access to medicines, indigenous rights and women rights.
Eli Lilly vs. Canada: Medicine patents
Biologic exclusivity provision stripped from revised USMCA deal
A provision of the United States-Mexico-Canada Agreement on trade that would have guaranteed 10 years of market exclusivity for biologic drugs was removed.